Literature DB >> 15872060

5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats.

Chandikumar S Elangbam1, Ruth M Lightfoot, Lawrence W Yoon, Donald R Creech, Robert S Geske, Christopher W Crumbley, Lisa D Gates, Henry G Wall.   

Abstract

5-Hydroxytryptamine-2B receptor (5HT2BR) stimulation is known to cause fibroblast mitogenesis, and the mitogenic effect has been proposed to trigger valvular heart disease in humans. In this study, we used real-time polymerase chain reaction (TaqMan) to quantify transcript levels of 5HT2B, 5HT2C, and 5HT1B receptors and immunohistochemistry (IHC) to detect the tissue localization of these receptors in the normal heart valves of cynomolgus (CM) monkeys and Sprague-Dawley (S-D) rats. In both species, positive immunostaining was noted for 5HT1B and 5HT2B receptors in mitral, tricuspid, aortic, and pulmonary valves, and the cell types showing positive staining were interstitial cells and endothelial cells lining the valve leaflet. In CM monkeys, 5HT2CR was expressed only in the endothelial cells lining the leaflet, whereas S-D valves were negative for this receptor. IHC results were correlated with 5HT2B and 5HT1B receptor transcripts for all four valves. However, 5HT2C receptor transcripts were lower than 5HT2B or 5HT1B in all CM monkey valves, whereas 5HT2C transcripts were below the level of detection in any of the S-D rat valves. Our data showed the expression of 5HT2B, 5HT1B, and 5HT2C receptors in the normal heart valves of CM monkeys and S-D rats, and IHC and TaqMan techniques may be used to study the potential mechanism of compounds with 5HT2BR agonist activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15872060     DOI: 10.1369/jhc.4A6500.2005

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

1.  An inherent acceleratory effect of insulin on small intestinal transit and its pharmacological characterization in normal mice.

Authors:  Murali-Krishna-Reddy Peddyreddy; Steven Aibor Dkhar; Subramanian Ramaswamy; Amrithraj Theophilus Naveen; Deepak Gopal Shewade
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  The role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors.

Authors:  Estelle Ayme-Dietrich; Roland Lawson; Francine Côté; Claudia de Tapia; Sylvia Da Silva; Claudine Ebel; Béatrice Hechler; Christian Gachet; Jérome Guyonnet; Hélène Rouillard; Jordane Stoltz; Emily Quentin; Sophie Banas; François Daubeuf; Nelly Frossard; Bernard Gasser; Jean-Philippe Mazzucotelli; Olivier Hermine; Luc Maroteaux; Laurent Monassier
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

Review 3.  Serotonin receptors and heart valve disease--it was meant 2B.

Authors:  Joshua D Hutcheson; Vincent Setola; Bryan L Roth; W David Merryman
Journal:  Pharmacol Ther       Date:  2011-04-02       Impact factor: 12.310

4.  Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

Authors:  Kathryn H Driesbaugh; Emanuela Branchetti; Juan B Grau; Samuel J Keeney; Kimberly Glass; Mark A Oyama; Nancy Rioux; Salma Ayoub; Michael S Sacks; John Quackenbush; Robert J Levy; Giovanni Ferrari
Journal:  J Mol Cell Cardiol       Date:  2017-12-30       Impact factor: 5.000

5.  The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.

Authors:  Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher
Journal:  Neuropsychopharmacology       Date:  2011-12-21       Impact factor: 7.853

6.  Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.

Authors:  Xi-Ping Huang; Vincent Setola; Prem N Yadav; John A Allen; Sarah C Rogan; Bonnie J Hanson; Chetana Revankar; Matt Robers; Chris Doucette; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2009-07-01       Impact factor: 4.436

Review 7.  Carcinoid syndrome: update on the pathophysiology and treatment.

Authors:  Anezka C Rubin de Celis Ferrari; João Glasberg; Rachel P Riechelmann
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

8.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.